source
- The capacity crunch in biopharma is a location problemCell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.BioPharma Dive · 2mo ago↗ source
- STAT+: Five years after disaster, a rare disease community gets new chance at treatmentSome boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.STAT · 2mo ago↗ source
- Opinion: What addiction medicine can teach us about depending on AIPeople gradually rely on AI to reduce the discomfort of thinking. For some, that can become a problem.STAT · 2mo ago↗ source